Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background & Aims</h3><p>Nonalcoholic fatty liver disease (NAFLD) is associated with elevation of many cytokines particularly IL‐6; however, the role of IL‐6 in NAFLD remains obscure. The aim of this study was to examine how myeloid‐specific IL‐6 signaling affects NAFLD via the regulation of anti‐fibrotic microRNA‐223 in myeloid cells.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Approach & Results</h3><p>Patients with NAFLD or nonalcoholic steatohepatitis (NASH) and healthy controls were recruited, and serum IL‐6 and soluble IL‐6 receptor α (sIL‐6Rα) were measured. Compared to controls, serum IL‐6 and sIL‐6Rα levels were elevated in NAFLD/NASH patients. IL‐6 levels correlated positively with the number of circulating leukocytes and monocytes. The role of IL‐6 in NAFLD was investigated in <i>Il6</i> knockout (KO) and <i>Il6</i> receptor A (<i>Il6ra</i>) conditional KO mice after high‐fat diet (HFD) feeding. HFD‐fed <i>Il6</i> KO mice had worse liver injury and fibrosis, but less inflammation compared to WT mice. Hepatocyte‐specific <i>Il6ra</i> KO mice had more steatosis and liver injury, whereas myeloid‐specific <i>Il6ra</i> KO mice had lower number of hepatic infiltrating macrophages and neutrophils with increased cell death of these cells but greater liver fibrosis than WT mice. Mechanistically, the increased liver fibrosis in HFD‐fed myeloid‐specific <i>Il6ra</i> KO mice was due to the reduction of anti‐fibrotic miR‐223 and subsequent upregulation of the miR‐223 target gene transcriptional activator with PDZ‐binding motif (TAZ), a well‐known factor to promote NASH‐fibrosis. <i>In vitro,</i> IL‐6 treatment upregulated exosome biogenesis‐related genes and subsequently promoted macrophages to release miR‐223‐enriched exosomes that were able to reduce pro‐fibrotic TAZ expression in hepatocytes via exosomal transfer. Finally, serum IL‐6 and miR‐223 levels were elevated and correlated with each other in NAFLD patients. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Myeloid‐specific IL‐6 signaling inhibits liver fibrosis via exosomal transfer of anti‐fibrotic miR‐223 into hepatocytes, providing novel therapeutic targets for NAFLD therapy.</p></section>

IL6 Derived from Macrophages under Intermittent Hypoxia Exacerbates NAFLD by Promoting Ferroptosis via MARCH3-Led Ubiquitylation of GPX4

Aberrant Hepatic Microrna Expression in Nonalcoholic Fatty Liver Disease

The role of ferroptosis in chronic intermittent hypoxia-induced liver injury in rats

Dysregulated autophagic activity induced in response to chronic intermittent hypoxia contributes to the pathogenesis of NAFLD

Intermittent hypoxia aggravates non-alcoholic fatty liver disease via RIPK3-dependent necroptosis-modulated Nrf2/NFκB signaling pathway

Association of Obstructive Sleep Apnea with Nonalcoholic Fatty Liver Disease: Evidence, Mechanism, and Treatment

Myeloid‐Cell–Specific IL‐6 Signaling Promotes MicroRNA‐223‐Enriched Exosome Production to Attenuate NAFLD‐Associated Fibrosis

Obeticholic acid and ferrostatin-1 differentially ameliorate non-alcoholic steatohepatitis in AMLN diet-fed ob/ob mice

The effects of intermittent hypoxia on hepatic expression of fatty acid translocase CD36 in lean and diet-induced obese mice

Untargeted Metabolomic Profiling of Liver in a Chronic Intermittent Hypoxia Mouse Model

Targeting ferroptosis alleviates methionine‐choline deficient (MCD)‐diet induced NASH by suppressing liver lipotoxicity

Long-term intermittent hypoxia in mice induces inflammatory pathways implicated in sleep apnea and steatohepatitis in humans

Bioinformatics analysis of potential ferroptosis and non-alcoholic fatty liver disease biomarkers

Decreased autophagosome biogenesis, reduced NRF2, and enhanced ferroptotic cell death are underlying molecular mechanisms of non-alcoholic fatty liver disease

Ferroptosis inhibitor liproxstatin-1 alleviates metabolic dysfunction-associated fatty liver disease in mice: potential involvement of PANoptosis

Neuronal ferroptosis and ferroptosis-mediated endoplasmic reticulum stress: Implications in cognitive dysfunction induced by chronic intermittent hypoxia in mice

Obstructive Sleep Apnea and Non-Alcoholic Fatty Liver Disease: Is the Liver Another Target?

Exploration and Validation of Ferroptosis-Associated Genes in ADAR1 Deletion-Induced NAFLD through RNA-seq Analysis

Silica nanoparticles induce liver lipid metabolism disorder via ACSL4-mediated ferroptosis

Identification and validation of ferroptosis-related hub genes in obstructive sleep apnea syndrome

Intermittent hypoxia-induced METTL3 downregulation facilitates MGLL-mediated lipolysis of adipocytes in OSAS